Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Lung Neoplasms 10Neoplasms 4Adenocarcinoma of Lung 4NSCLC 3Thoracic Neoplasms 2Respiratory Tract Diseases 2Lung Diseases 2Advanced Non-squamous Non-small-cell Lung Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PD-L1 Positive Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11Drug Therapy 9aflutinib 8Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NSCLC × apatinib × Thoracic × Clear all
NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
22 enrolled
Thoracic

NSCLC

NCT04506242 2020-09-09

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
74 enrolled
Thoracic

NSCLC

NCT03416231 2018-01-31

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Affiliated Hospital of North Sichuan Medical College

Phase 2 Unknown
20 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡